A Phase 3 interventional study of Cariprazine and Placebo in Schizophrenia, sponsored by AbbVie. Terminated at 52 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-10-20.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing cariprazine in Schizophrenia — 4 open to participants now, 4 under way, 2 of them phase 3. cariprazine · Schizophrenia.
Among the 23 studies testing cariprazine in Schizophrenia, this one is the 19th largest by enrollment, is the only one that started in 2022, is one of 8 in phase 3, and was the 18th registered.
3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.
Browse Schizophrenia studies →4 of the 23 studies testing cariprazine in Schizophrenia are open now, in 10 countries. Recruiting first, the newest first:
Mapi Pharma Ltd. · Sites in India, Israel
Ages 18–64
Gedeon Richter Plc. · Sites in United States, Bulgaria, Colombia and 5 more countries
Ages 13–17
New York State Psychiatric Institute
Ages 18–55
Bostal Drug Delivery Co., Ltd
Ages 18–65
By country, each count listing its studies:
cariprazine: first FDA approval 2015 (VRAYLAR), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 11 · Phase 3 14
First in 2006; this study’s year is marked. 1 started in 2022.
This study's enrollment of 34 is below the median of 71 across 2,947 interventional studies indexed under Schizophrenia.
Median enrollment 129 across the 23 interventional studies. Of the 18 that completed or were terminated, 14 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 23 have an industry lead sponsor. The 10 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
27 studies in Schizophrenia by AbbVie: 1 open now, 1 under way, none of them phase 3. Of 26 finished, 11 (42%) have results posted.
Among the 27 studies in Schizophrenia by AbbVie, this one is the 25th largest by enrollment, is one of 5 that started in 2022, is one of 8 in phase 3, and was the 25th registered.
AbbVie’s Schizophrenia studies by the year they started, since 2004.
3 of the studies testing cariprazine in Schizophrenia that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03817502Phase 3Gedeon Richter Plc.Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia | 2026-12-15 |
| NCT07722728Phase 3Bostal Drug Delivery Co., LtdA Study to Investigate Pharmacokinetics, Safety, and Tolerability of B2227 Extended-Release Injectable Suspension and Vraylar® in Participants With Schizophrenia | 2027-08 |
| NCT07185815Mapi Pharma Ltd.Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for Treatment With Oral Cariprazine | 2026-12-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 23 studies testing cariprazine in Schizophrenia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 27 in Schizophrenia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Schizophrenia is a common and severe psychiatric illness characterized by extreme disturbances of cognition and thought, affecting language, perception and sense of self. This study will assess how safe and effective cariprazine is in treating adult participants with schizophrenia in Japan and Taiwan. Adverse events and change in disease activity will be assessed.
Cariprazine (VRAYLAR) is an approved drug for the treatment of schizophrenia in the United States. In the first 6-week period, participants are placed in 1 of 2 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 2 chance that participants will be assigned to placebo. In the next 18-week period, participants will have the option to receive 1 of 3 doses of cariprazine. Approximately 250 adult participants, 18-65 years of age with schizophrenia will be enrolled in approximately 55 sites across Taiwan and Japan.
Participants will receive oral capsules of Cariprazine or placebo for the 6-week Double-blind Period (DBP). Upon completion of 6-week DBP, participants will be eligible to receive oral capsules of Cariprazine for additional 18 weeks in the Blinded Extension Period (BEP), followed by an 8-week safety follow-up period.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Per the final protocol amendment 3, the number of dosing arms in the 6-week DBP of the study changed from 3 to 2. Participants enrolled in the study through Protocol Amendment 2 and who were randomized to the arm that was eliminated, remained in that arm through DBP and their data are displayed by that arm for the DBP portion of the study in participant flow, baseline characteristics and safety sections. Data for all endpoints are presented as planned per final SAP.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
- History of medical conditions or any other reason that the investigator (or subinvestigator) determines would interfere with the participant's participation in this study or would make the participant an unsuitable candidate to receive study drug.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive cariprazine Dose A daily for 6 weeks. Upon completion of 6 week treatment period, participants will have option to receive cariprazine Dose B for 18 weeks.
Drug: Cariprazine
Participants will receive placebo daily for 6 weeks. Upon completion of 6 week treatment period, participants will have option to receive cariprazine Dose B for 18 weeks.
Drug: Cariprazine · Drug: Placebo
Oral Capsule
Also known as: VRAYLAR
Oral Capsule
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first dose of study drug.
Time frame: From first dose of study drug until 8 weeks following last dose of study drug (up to 32 weeks)
Change in SCI-PANSS Total Score From Baseline (Wk 0) to Week 6.
Structured Clinical Interview for the Positive and Negative Syndrome Scale (SCI-PANSS) is a 30-item clinician-reported rating scale which assesses both the positive and negative symptom syndromes of patients with schizophrenia. This assessment provides scores in 9 clinical domains, including a positive syndrome, a negative syndrome, depression, a composite index, and general psychopathology. Each item is scored on a 7-point scale with responses ranging from 1 (absent) to 7 (extreme). Higher values represent a worse outcome. The SCI-PANSS total score can range from 30 to 210. A negative change from baseline indicates improvement.
Time frame: Baseline (Wk 0) to Week 6
Change in CGI-S Score From Baseline (Wk 0) to Week 6
Clinical Global Impression-Severity (CGI-S) is a single, clinician-reported item that measures the clinician's impression of a participant's current anxiety severity considering their total clinical experience with the patient population. The measure uses a 7-point Likert rating scale with responses ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). The total CGI-S score can range from 1 to 7. A higher score indicates more severe illness. A negative change from baseline indicates improvement.
Time frame: Baseline (Wk 0) to Week 6
Change in SCI-PANSS Positive Symptom Score From Baseline (Wk 0) to Week 6
Structured Clinical Interview for the Positive and Negative Syndrome Scale (SCI-PANSS) is a 30-item clinician-reported rating scale which assesses both the positive and negative symptom syndromes of patients with schizophrenia. This assessment provides scores in 9 clinical domains, including a positive syndrome, a negative syndrome, depression, a composite index, and general psychopathology. Each item is scored on a 7-point scale with responses ranging from 1 (absent) to 7 (extreme). Higher values represent a worse outcome. The SCI-PANSS total score can range from 30 to 210. A negative change from baseline indicates improvement.
Time frame: Baseline (Wk 0) to Week 6
Change in NSA-16 Total Score to Baseline (Wk 0) to Week 6
Negative Symptom Assessment-16 (NSA-16) is a 16-item clinician-reported scale covering 5 areas or domains: communication, affect, social involvement, motivation, and retardation. It is designed to assess negative symptoms of patients with schizophrenia. Each item or behavior is rated on a 6-point scale ranging from 1 (not reduced) to 6 (severely reduced or absent). Higher values represent a worse outcome. The total NSA-16 score can range from 16 to 96. A negative change from baseline indicates improvement.
Time frame: Baseline (Wk 0) to Week 6
Change in SCI-PANSS Negative Symptom Score From Baseline (Wk 0) to Week 6
Structured Clinical Interview for the Positive and Negative Syndrome Scale (SCI-PANSS) is a 30-item clinician-reported rating scale which assesses both the positive and negative symptom syndromes of patients with schizophrenia. This assessment provides scores in 9 clinical domains, including a positive syndrome, a negative syndrome, depression, a composite index, and general psychopathology. Each item is scored on a 7-point scale with responses ranging from 1 (absent) to 7 (extreme). Higher values represent a worse outcome. The SCI-PANSS total score can range from 30 to 210. A negative change from baseline indicates improvement.
Time frame: Baseline (Wk 0) to Week 6
Change in SCI-PANSS Negative Factor Score From Baseline (Wk 0) to Week 6
Structured Clinical Interview for the Positive and Negative Syndrome Scale (SCI-PANSS) is a 30-item clinician-reported rating scale which assesses both the positive and negative symptom syndromes of patients with schizophrenia. This assessment provides scores in 9 clinical domains, including a positive syndrome, a negative syndrome, depression, a composite index, and general psychopathology. Each item is scored on a 7-point scale with responses ranging from 1 (absent) to 7 (extreme). Higher values represent a worse outcome. The SCI-PANSS total score can range from 30 to 210. A negative change from baseline indicates improvement.
Time frame: Baseline (Wk 0) to Week 6
Change in SCI-PANSS Total Score From Baseline (Wk 0) and Week 6 to Week 24
Structured Clinical Interview for the Positive and Negative Syndrome Scale (SCI-PANSS) is a 30-item clinician-reported rating scale which assesses both the positive and negative symptom syndromes of patients with schizophrenia. This assessment provides scores in 9 clinical domains, including a positive syndrome, a negative syndrome, depression, a composite index, and general psychopathology. Each item is scored on a 7-point scale with responses ranging from 1 (absent) to 7 (extreme). Higher values represent a worse outcome. The SCI-PANSS total score can range from 30 to 210. A negative change from baseline indicates improvement.
Time frame: Baseline (Wk 0) and Week 6 to Week 24
Change in CGI-S Score From Baseline (Wk 0) and Week 6 to Week 24
Clinical Global Impression-Severity (CGI-S) is a single, clinician-reported item that measures the clinician's impression of a participant's current anxiety severity considering their total clinical experience with the patient population. The measure uses a 7-point Likert rating scale with responses ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). The total CGI-S score can range from 1 to 7. A higher score indicates more severe illness. A negative change from baseline indicates improvement.
Time frame: Baseline (Wk 0) and Week 6 to Week 24
Change in SCI-PANSS Positive Symptom Score From Baseline (Wk 0) and Week 6 to Week 24
Structured Clinical Interview for the Positive and Negative Syndrome Scale (SCI-PANSS) is a 30-item clinician-reported rating scale which assesses both the positive and negative symptom syndromes of patients with schizophrenia. This assessment provides scores in 9 clinical domains, including a positive syndrome, a negative syndrome, depression, a composite index, and general psychopathology. Each item is scored on a 7-point scale with responses ranging from 1 (absent) to 7 (extreme). Higher values represent a worse outcome. The SCI-PANSS total score can range from 30 to 210. A negative change from baseline indicates improvement.
Time frame: Baseline (Wk 0) and Week 6 to Week 24
Change in NSA-16 Total Score From Baseline (Wk 0) and Week 6 to Week 24
Negative Symptom Assessment-16 (NSA-16) is a 16-item clinician-reported scale covering 5 areas or domains: communication, affect, social involvement, motivation, and retardation. It is designed to assess negative symptoms of patients with schizophrenia. Each item or behavior is rated on a 6-point scale ranging from 1 (not reduced) to 6 (severely reduced or absent). Higher values represent a worse outcome. The total NSA-16 score can range from 16 to 96. A negative change from baseline indicates improvement.
Time frame: Baseline (Wk 0) and Week 6 to Week 24
Change in SCI-PANSS Negative Symptom Score From Baseline (Wk 0) and Week 6 to Week 24
Structured Clinical Interview for the Positive and Negative Syndrome Scale (SCI-PANSS) is a 30-item clinician-reported rating scale which assesses both the positive and negative symptom syndromes of patients with schizophrenia. This assessment provides scores in 9 clinical domains, including a positive syndrome, a negative syndrome, depression, a composite index, and general psychopathology. Each item is scored on a 7-point scale with responses ranging from 1 (absent) to 7 (extreme). Higher values represent a worse outcome. The SCI-PANSS total score can range from 30 to 210. A negative change from baseline indicates improvement.
Time frame: Baseline (Wk 0) and Week 6 to Week 24
Change in SCI-PANSS Negative Factor Score From Baseline (Wk 0) and Week 6 to Week 24
Structured Clinical Interview for the Positive and Negative Syndrome Scale (SCI-PANSS) is a 30-item clinician-reported rating scale which assesses both the positive and negative symptom syndromes of patients with schizophrenia. This assessment provides scores in 9 clinical domains, including a positive syndrome, a negative syndrome, depression, a composite index, and general psychopathology. Each item is scored on a 7-point scale with responses ranging from 1 (absent) to 7 (extreme). Higher values represent a worse outcome. The SCI-PANSS total score can range from 30 to 210. A negative change from baseline indicates improvement.
Time frame: Baseline (Wk 0) and Week 6 to Week 24
| Milestone | DBP Placebo | DBP Cariprazine 3 mg | DBP Cariprazine 6 mg | BEP Cariprazine 1.5 mg | BEP Cariprazine 3 mg | BEP Cariprazine 6 mg | SF DBP Placebo | SF DBP Cariprazine 3 mg | SF DBP Cariprazine 6 mg | SF BEP Cariprazine 1.5 mg | SF BEP Cariprazine 3 mg | SF BEP Cariprazine 6 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 16 | 5 | 13 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 15 | 4 | 11 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 1 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | DBP Placebo | DBP Cariprazine 3 mg | DBP Cariprazine 6 mg | BEP Cariprazine 1.5 mg | BEP Cariprazine 3 mg | BEP Cariprazine 6 mg | SF DBP Placebo | SF DBP Cariprazine 3 mg | SF DBP Cariprazine 6 mg | SF BEP Cariprazine 1.5 mg | SF BEP Cariprazine 3 mg | SF BEP Cariprazine 6 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 10 | 4 | 10 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 8 | 4 | 7 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 2 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | DBP Placebo | DBP Cariprazine 3 mg | DBP Cariprazine 6 mg | BEP Cariprazine 1.5 mg | BEP Cariprazine 3 mg | BEP Cariprazine 6 mg | SF DBP Placebo | SF DBP Cariprazine 3 mg | SF DBP Cariprazine 6 mg | SF BEP Cariprazine 1.5 mg | SF BEP Cariprazine 3 mg | SF BEP Cariprazine 6 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 15 | 4 | 11 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 1 | 4 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 10 | 3 | 7 | 0 | 0 | 0 |
| Milestone | DBP Placebo | DBP Cariprazine 3 mg | DBP Cariprazine 6 mg | BEP Cariprazine 1.5 mg | BEP Cariprazine 3 mg | BEP Cariprazine 6 mg | SF DBP Placebo | SF DBP Cariprazine 3 mg | SF DBP Cariprazine 6 mg | SF BEP Cariprazine 1.5 mg | SF BEP Cariprazine 3 mg | SF BEP Cariprazine 6 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10 | 4 | 10 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10 | 4 | 10 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first dose of study drug.
| Participants | DBP Placebo | DBP Cariprazine 3 mg | DBP Cariprazine 6 mg |
|---|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 12 | 2 | 10 |
Structured Clinical Interview for the Positive and Negative Syndrome Scale (SCI-PANSS) is a 30-item clinician-reported rating scale which assesses both the positive and negative symptom syndromes of patients with schizophrenia. This assessment provides scores in 9 clinical domains, including a positive syndrome, a negative syndrome, depression, a composite index, and general psychopathology. Each item is scored on a 7-point scale with responses ranging from 1 (absent) to 7 (extreme). Higher values represent a worse outcome. The SCI-PANSS total score can range from 30 to 210. A negative change from baseline indicates improvement.
| score on a scale | DBP Placebo | DBP Cariprazine 3 mg | DBP Cariprazine 6 mg |
|---|---|---|---|
| Change in SCI-PANSS Total Score From Baseline (Wk 0) to Week 6. | -15.2 ± 12.21 | -5.6 ± 10.38 | -30.2 ± 17.47 |
Clinical Global Impression-Severity (CGI-S) is a single, clinician-reported item that measures the clinician's impression of a participant's current anxiety severity considering their total clinical experience with the patient population. The measure uses a 7-point Likert rating scale with responses ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). The total CGI-S score can range from 1 to 7. A higher score indicates more severe illness. A negative change from baseline indicates improvement.
| score on a scale | DBP Placebo | DBP Cariprazine 3 mg | DBP Cariprazine 6 mg |
|---|---|---|---|
| Change in CGI-S Score From Baseline (Wk 0) to Week 6 | -0.6 ± 0.92 | -0.4 ± 0.55 | -1.3 ± 1.25 |
Structured Clinical Interview for the Positive and Negative Syndrome Scale (SCI-PANSS) is a 30-item clinician-reported rating scale which assesses both the positive and negative symptom syndromes of patients with schizophrenia. This assessment provides scores in 9 clinical domains, including a positive syndrome, a negative syndrome, depression, a composite index, and general psychopathology. Each item is scored on a 7-point scale with responses ranging from 1 (absent) to 7 (extreme). Higher values represent a worse outcome. The SCI-PANSS total score can range from 30 to 210. A negative change from baseline indicates improvement.
| score on a scale | DBP Placebo | DBP Cariprazine 3 mg | DBP Cariprazine 6 mg |
|---|---|---|---|
| Change in SCI-PANSS Positive Symptom Score From Baseline (Wk 0) to Week 6 | -4.7 ± 4.67 | -2.2 ± 3.35 | -8.7 ± 4.00 |
Negative Symptom Assessment-16 (NSA-16) is a 16-item clinician-reported scale covering 5 areas or domains: communication, affect, social involvement, motivation, and retardation. It is designed to assess negative symptoms of patients with schizophrenia. Each item or behavior is rated on a 6-point scale ranging from 1 (not reduced) to 6 (severely reduced or absent). Higher values represent a worse outcome. The total NSA-16 score can range from 16 to 96. A negative change from baseline indicates improvement.
| score on a scale | DBP Placebo | DBP Cariprazine 3 mg | DBP Cariprazine 6 mg |
|---|---|---|---|
| Change in NSA-16 Total Score to Baseline (Wk 0) to Week 6 | -3.2 ± 7.49 | -2.8 ± 9.20 | -14.5 ± 8.28 |
Structured Clinical Interview for the Positive and Negative Syndrome Scale (SCI-PANSS) is a 30-item clinician-reported rating scale which assesses both the positive and negative symptom syndromes of patients with schizophrenia. This assessment provides scores in 9 clinical domains, including a positive syndrome, a negative syndrome, depression, a composite index, and general psychopathology. Each item is scored on a 7-point scale with responses ranging from 1 (absent) to 7 (extreme). Higher values represent a worse outcome. The SCI-PANSS total score can range from 30 to 210. A negative change from baseline indicates improvement.
| score on a scale | DBP Placebo | DBP Cariprazine 3 mg | DBP Cariprazine 6 mg |
|---|---|---|---|
| Change in SCI-PANSS Negative Symptom Score From Baseline (Wk 0) to Week 6 | -3.5 ± 3.86 | -0.2 ± 3.27 | -8.1 ± 5.30 |
Structured Clinical Interview for the Positive and Negative Syndrome Scale (SCI-PANSS) is a 30-item clinician-reported rating scale which assesses both the positive and negative symptom syndromes of patients with schizophrenia. This assessment provides scores in 9 clinical domains, including a positive syndrome, a negative syndrome, depression, a composite index, and general psychopathology. Each item is scored on a 7-point scale with responses ranging from 1 (absent) to 7 (extreme). Higher values represent a worse outcome. The SCI-PANSS total score can range from 30 to 210. A negative change from baseline indicates improvement.
| score on a scale | DBP Placebo | DBP Cariprazine 3 mg | DBP Cariprazine 6 mg |
|---|---|---|---|
| Change in SCI-PANSS Negative Factor Score From Baseline (Wk 0) to Week 6 | -3.8 ± 3.71 | -0.4 ± 3.78 | -9.1 ± 6.82 |
Structured Clinical Interview for the Positive and Negative Syndrome Scale (SCI-PANSS) is a 30-item clinician-reported rating scale which assesses both the positive and negative symptom syndromes of patients with schizophrenia. This assessment provides scores in 9 clinical domains, including a positive syndrome, a negative syndrome, depression, a composite index, and general psychopathology. Each item is scored on a 7-point scale with responses ranging from 1 (absent) to 7 (extreme). Higher values represent a worse outcome. The SCI-PANSS total score can range from 30 to 210. A negative change from baseline indicates improvement.
| score on a scale | BEP Cariprazine 1.5 mg | BEP Cariprazine 3 mg | BEP Cariprazine 6 mg |
|---|---|---|---|
| Baseline (Wk 0) to Week 24 | -19.2 ± 19.52 | -19.3 ± 30.09 | -22.5 ± 25.16 |
| Week 6 to Week 24 | -4.0 ± 16.05 | 2.0 ± 4.58 | 6.0 ± 17.51 |
Clinical Global Impression-Severity (CGI-S) is a single, clinician-reported item that measures the clinician's impression of a participant's current anxiety severity considering their total clinical experience with the patient population. The measure uses a 7-point Likert rating scale with responses ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). The total CGI-S score can range from 1 to 7. A higher score indicates more severe illness. A negative change from baseline indicates improvement.
| score on a scale | BEP Cariprazine 1.5 mg | BEP Cariprazine 3 mg | BEP Cariprazine 6 mg |
|---|---|---|---|
| Baseline (Wk 0) to Week 24 | -0.8 ± 0.84 | -1.3 ± 2.31 | -1.0 ± 0.82 |
| Week 6 to Week 24 | -0.4 ± 1.14 | 0.0 ± 0.00 | 0.0 ± 0.82 |
Structured Clinical Interview for the Positive and Negative Syndrome Scale (SCI-PANSS) is a 30-item clinician-reported rating scale which assesses both the positive and negative symptom syndromes of patients with schizophrenia. This assessment provides scores in 9 clinical domains, including a positive syndrome, a negative syndrome, depression, a composite index, and general psychopathology. Each item is scored on a 7-point scale with responses ranging from 1 (absent) to 7 (extreme). Higher values represent a worse outcome. The SCI-PANSS total score can range from 30 to 210. A negative change from baseline indicates improvement.
| score on a scale | BEP Cariprazine 1.5 mg | BEP Cariprazine 3 mg | BEP Cariprazine 6 mg |
|---|---|---|---|
| Baseline (Wk 0) to Week 24 | -5.2 ± 5.36 | -4.3 ± 7.51 | -6.8 ± 6.60 |
| Week 6 to Week 24 | -0.2 ± 4.38 | 0.3 ± 0.58 | 1.5 ± 6.03 |
Negative Symptom Assessment-16 (NSA-16) is a 16-item clinician-reported scale covering 5 areas or domains: communication, affect, social involvement, motivation, and retardation. It is designed to assess negative symptoms of patients with schizophrenia. Each item or behavior is rated on a 6-point scale ranging from 1 (not reduced) to 6 (severely reduced or absent). Higher values represent a worse outcome. The total NSA-16 score can range from 16 to 96. A negative change from baseline indicates improvement.
| score on a scale | BEP Cariprazine 1.5 mg | BEP Cariprazine 3 mg | BEP Cariprazine 6 mg |
|---|---|---|---|
| Baseline (Wk 0) to Week 24 | -11.6 ± 13.52 | -5.0 ± 14.00 | -13.3 ± 20.19 |
| Week 6 to Week 24 | -7.6 ± 18.28 | 2.7 ± 5.51 | -1.8 ± 11.18 |
Structured Clinical Interview for the Positive and Negative Syndrome Scale (SCI-PANSS) is a 30-item clinician-reported rating scale which assesses both the positive and negative symptom syndromes of patients with schizophrenia. This assessment provides scores in 9 clinical domains, including a positive syndrome, a negative syndrome, depression, a composite index, and general psychopathology. Each item is scored on a 7-point scale with responses ranging from 1 (absent) to 7 (extreme). Higher values represent a worse outcome. The SCI-PANSS total score can range from 30 to 210. A negative change from baseline indicates improvement.
| score on a scale | BEP Cariprazine 1.5 mg | BEP Cariprazine 3 mg | BEP Cariprazine 6 mg |
|---|---|---|---|
| Baseline (Wk 0) to Week 24 | -6.4 ± 3.85 | -5.0 ± 6.24 | -5.3 ± 9.64 |
| Week 6 to Week 24 | -2.8 ± 4.09 | -1.3 ± 2.52 | 2.3 ± 4.19 |
Structured Clinical Interview for the Positive and Negative Syndrome Scale (SCI-PANSS) is a 30-item clinician-reported rating scale which assesses both the positive and negative symptom syndromes of patients with schizophrenia. This assessment provides scores in 9 clinical domains, including a positive syndrome, a negative syndrome, depression, a composite index, and general psychopathology. Each item is scored on a 7-point scale with responses ranging from 1 (absent) to 7 (extreme). Higher values represent a worse outcome. The SCI-PANSS total score can range from 30 to 210. A negative change from baseline indicates improvement.
| score on a scale | BEP Cariprazine 1.5 mg | BEP Cariprazine 3 mg | BEP Cariprazine 6 mg |
|---|---|---|---|
| Baseline (Wk 0) to Week 24 | -5.2 ± 4.09 | -6.7 ± 9.29 | -6.0 ± 9.76 |
| Week 6 to Week 24 | -1.6 ± 3.78 | -1.0 ± 1.00 | 2.0 ± 4.16 |
Collected over All-cause mortality were reported from enrollment to the end of study. In the DBP, median time on follow up (median time subjects were followed) was 42.0 days (d) for all arms (DBP: Pbo, C 3mg, and C 6mg). In the BEP, median time on follow up was 117.5, 126.0, and 97.5d for BEP: C1.5mg, C 3mg, and C 6mg, respectively. In the SF DBP, median time on follow up was 57.0, 1.0, and 47.0d for SF DBP: Pbo, C 3mg, and C 6mg, respectively.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DBP Placebo | 0/16 (0%) | 0/16 (0%) | 12/16 (75%) |
| DBP Cariprazine 3 mg | 0/5 (0%) | 0/5 (0%) | 2/5 (40%) |
| DBP Cariprazine 6 mg | 0/13 (0%) | 0/13 (0%) | 10/13 (76.9%) |
| BEP Cariprazine 1.5 mg | 0/10 (0%) | 1/10 (10%) | 7/10 (70%) |
| BEP Cariprazine 3 mg | 0/4 (0%) | 1/4 (25%) | 3/4 (75%) |
| BEP Cariprazine 6 mg | 0/10 (0%) | 0/10 (0%) | 6/10 (60%) |
| SF DBP Placebo | 0/5 (0%) | 0/5 (0%) | 3/5 (60%) |
| SF DBP Cariprazine 3 mg | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
| SF DBP Cariprazine 6 mg | 0/4 (0%) | 1/4 (25%) | 2/4 (50%) |
| SF BEP Cariprazine 1.5 mg | 0/10 (0%) | 0/10 (0%) | 4/10 (40%) |
| SF BEP Cariprazine 3 mg | 0/4 (0%) | 1/4 (25%) | 0/4 (0%) |
| SF BEP Cariprazine 6 mg | 0/10 (0%) | 0/10 (0%) | 2/10 (20%) |
| Event | DBP Placebo | DBP Cariprazine 3 mg | DBP Cariprazine 6 mg | BEP Cariprazine 1.5 mg | BEP Cariprazine 3 mg | BEP Cariprazine 6 mg | SF DBP Placebo | SF DBP Cariprazine 3 mg | SF DBP Cariprazine 6 mg | SF BEP Cariprazine 1.5 mg | SF BEP Cariprazine 3 mg | SF BEP Cariprazine 6 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AGITATIONPsychiatric disorders | 0/16 | 0/5 | 0/13 | 0/10 | 1/4 | 0/10 | 0/5 | 0/1 | 0/4 | 0/10 | 0/4 | 0/10 |
| SCHIZOPHRENIAPsychiatric disorders | 0/16 | 0/5 | 0/13 | 1/10 | 0/4 | 0/10 | 0/5 | 0/1 | 1/4 | 0/10 | 1/4 | 0/10 |
| Event | DBP Placebo | DBP Cariprazine 3 mg | DBP Cariprazine 6 mg | BEP Cariprazine 1.5 mg | BEP Cariprazine 3 mg | BEP Cariprazine 6 mg | SF DBP Placebo | SF DBP Cariprazine 3 mg | SF DBP Cariprazine 6 mg | SF BEP Cariprazine 1.5 mg | SF BEP Cariprazine 3 mg | SF BEP Cariprazine 6 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| COVID-19Infections and infestations | 0/16 | 0/5 | 0/13 | 4/10 | 0/4 | 1/10 | 1/5 | 0/1 | 0/4 | 0/10 | 0/4 | 0/10 |
| EXTRAPYRAMIDAL DISORDERNervous system disorders | 0/16 | 2/5 | 0/13 | 0/10 | 0/4 | 0/10 | 0/5 | 0/1 | 0/4 | 0/10 | 0/4 | 0/10 |
| AKATHISIANervous system disorders | 1/16 | 0/5 | 4/13 | 0/10 | 1/4 | 1/10 | 0/5 | 0/1 | 0/4 | 0/10 | 0/4 | 0/10 |
| CONSTIPATIONGastrointestinal disorders | 1/16 | 1/5 | 2/13 | 1/10 | 0/4 | 1/10 | 0/5 | 0/1 | 1/4 | 0/10 | 0/4 | 0/10 |
| WOUNDInjury, poisoning and procedural complications | 0/16 | 0/5 | 0/13 | 0/10 | 1/4 | 0/10 | 0/5 | 0/1 | 0/4 | 0/10 | 0/4 | 0/10 |
| WEIGHT DECREASEDInvestigations | 0/16 | 0/5 | 1/13 | 0/10 | 1/4 | 0/10 | 0/5 | 0/1 | 0/4 | 1/10 | 0/4 | 0/10 |
| MIGRAINENervous system disorders | 0/16 | 0/5 | 0/13 | 0/10 | 0/4 | 0/10 | 0/5 | 0/1 | 1/4 | 0/10 | 0/4 | 0/10 |
| ANXIETYPsychiatric disorders | 0/16 | 0/5 | 0/13 | 0/10 | 1/4 | 0/10 | 0/5 | 0/1 | 0/4 | 0/10 | 0/4 | 0/10 |
| LOGORRHOEAPsychiatric disorders | 0/16 | 0/5 | 0/13 | 0/10 | 1/4 | 0/10 | 0/5 | 0/1 | 0/4 | 0/10 | 0/4 | 0/10 |
| SCHIZOPHRENIAPsychiatric disorders | 4/16 | 1/5 | 0/13 | 0/10 | 0/4 | 1/10 | 0/5 | 0/1 | 0/4 | 0/10 | 0/4 | 0/10 |
Safety Population included all randomized participants who received at least 1 dose of study drug.
| Age, Continuous(years) | DBP Placebo | DBP Cariprazine 3 mg | DBP Cariprazine 6 mg | Total |
|---|---|---|---|---|
| Mean | 42.2 ± 11.76 | 40.4 ± 13.70 | 43.7 ± 10.88 | 42.5 ± 11.40 |
| Sex: Female, Male(Participants) | DBP Placebo | DBP Cariprazine 3 mg | DBP Cariprazine 6 mg | Total |
|---|---|---|---|---|
| Female | 6 | 1 | 6 | 13 |
| Male | 10 | 4 | 7 | 21 |
| Ethnicity (NIH/OMB)(Participants) | DBP Placebo | DBP Cariprazine 3 mg | DBP Cariprazine 6 mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 16 | 5 | 13 | 34 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | DBP Placebo | DBP Cariprazine 3 mg | DBP Cariprazine 6 mg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 16 | 5 | 13 | 34 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| SCI-PANSS Total Score at Baseline(score on a scale) | DBP Placebo | DBP Cariprazine 3 mg | DBP Cariprazine 6 mg | Total |
|---|---|---|---|---|
| Mean | 94.6 ± 8.70 | 99.8 ± 8.17 | 91.8 ± 7.37 | 94.3 ± 8.33 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Data sharing details ↗ · vivli.org
Ran from Aug 2022 to primary completion in Sep 2024, 25 months.
Results were first posted in Oct 2025, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cariprazine